Literature DB >> 25528389

Radioimmunotherapy in allogeneic nonmyeloablative conditioning for B cell lymphoma: should we use it more often?

Issa F Khouri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25528389      PMCID： PMC4376115          DOI： 10.1016/j.bbmt.2014.12.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  6 in total

1.  A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.

Authors:  Nitin Jain; William Wierda; Alessandra Ferrajoli; Franklin Wong; Susan Lerner; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

2.  Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

Authors:  Ryan D Cassaday; Barry E Storer; Mohamed L Sorror; Brenda M Sandmaier; Katherine A Guthrie; David G Maloney; Joseph G Rajendran; John M Pagel; Mary E Flowers; Damian J Green; Andrew R Rezvani; Rainer F Storb; Oliver W Press; Ajay K Gopal
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-01       Impact factor: 5.742

3.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

4.  Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

Authors:  Ajay K Gopal; Oliver W Press; Shani M Wilbur; David G Maloney; John M Pagel
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

5.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

Authors:  Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

6.  Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Authors:  Issa F Khouri; Rima M Saliba; William D Erwin; Barry I Samuels; Martin Korbling; L Jeffrey Medeiros; Rosamar Valverde; Amin M Alousi; Paolo Anderlini; Qaiser Bashir; Stefan Ciurea; Alison M Gulbis; Marcos de Lima; Chitra Hosing; Partow Kebriaei; Uday R Popat; Nathan Fowler; Sattva S Neelapu; Felipe Samaniego; Richard E Champlin; Homer A Macapinlac
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.